Page 1,871«..1020..1,8701,8711,8721,873..1,8801,890..»

Ethics of Human Cloning and Stem Cell Research

Posted: January 30, 2015 at 12:56 pm

Summary Notes for Members of the California State Legislature on

A report from "California Cloning: A Dialogue on State Regulation" Held at Santa Clara University, October 12, 2001

Cloning Californians? Report of the California Advisory Committee on Human Cloning January 11, 2002 Sacramento, CA

Science and Technology Perspectives Religious Perspectives Ethics Perspectives Legal Perspectives Useful Web Resources

"California Cloning: A Dialogue on State Regulation" was convened October 12, 2001, by the Markkula Center for Applied Ethics at Santa Clara University. Its purpose was to bring together experts from the fields of science, religion, ethics, and law to discuss how the state of California should proceed in regulating human cloning and stem cell research.

A framework for discussing the issue was provided by Center Director of Biotechnology and Health Care Ethics Margaret McLean, who also serves on the California State Advisory Committee on Human Cloning. In 1997, the California legislature declared a "five year moratorium on cloning of an entire human being" and requested that "a panel of representatives from the fields of medicine, religion, biotechnology, genetics, law, bioethics and the general public" be established to evaluate the "medical, ethical and social implications" of human cloning (SB 1344). This 12-member Advisory Committee on Human Cloning convened five public meetings, each focusing on a particular aspect of human cloning: e.g., reproductive cloning, and cloning technology and stem cells. The committee is drafting a report to the legislature that is due on December 31, 2001. The report will discuss the science of cloning, and the ethical and legal considerations of applications of cloning technology. It will also set out recommendations to the legislature regarding regulation of human cloning. The legislature plans to take up this discussion after January. The moratorium expires the end of 2002.

What should the state do at that point? More than 80 invited guests came to SCU for "California Cloning" to engage in a dialogue on that question. These included scientists, theologians, businesspeople from the biotechnology industry, bioethicists, legal scholars, representatives of non-profits, and SCU faculty. Keynote Speaker Ursula Goodenough, professor of biology at Washington University and author of Genetics, set the issues in context with her talk, "A Religious Naturalist Thinks About Bioethics." Four panels addressed the specific scientific, religious, ethical, and legal implications of human reproductive cloning and stem cell research. This document gives a brief summary of the issues as they were raised by the four panels.

Science and Biotechnology Perspectives

Thomas Okarma, CEO of Geron Corp., launched this panel with an overview of regenerative medicine and distinguished between reproductive cloning and human embryonic stem cell research. He helped the audience understand the science behind the medical potential of embryonic stem cell research, with an explanation of the procedures for creating stem cell lines and the relationship of this field to telomere biology and genetics. No brief summary could do justice to the science. The reader is referred to the report of the National Bioethics Advisory Committee (http://bioethics.georgetown.edu/nbac/stemcell.pdf) for a good introduction.

Responding to Okarma, were J. William Langston, president of the Parkinsons Institute, and Phyllis Gardner, associate professor of medicine and former dean for medical education at Stanford University. Both discussed the implications of the presidents recent restrictions on stem cell research for the non-profit sector. Langston compared the current regulatory environment to the Reagan era ban on fetal cell research, which he believed was a serious setback for Parkinsons research. He also pointed out that stem cell research was only being proposed using the thousands of embryos that were already being created in the process of fertility treatments. These would ultimately be disposed of in any event, he said, arguing that it would be better to allow them to serve some function rather than be destroyed. President Bush has confined federally-funded research to the 64 existing stem cell lines, far too few in Langstons view. In addition, Langston opposed bans on government funding for stem cell research because of the opportunities for public review afforded by the process of securing government grants.

Here is the original post:
Ethics of Human Cloning and Stem Cell Research

Posted in Mississippi Stem Cells | Comments Off on Ethics of Human Cloning and Stem Cell Research

San Diego Team Wins $1.7 Million Grant from Stem Cell Agency to Develop Quality Control Methods

Posted: January 30, 2015 at 12:53 pm

Contact Information

Available for logged-in reporters only

Newswise LA JOLLA, CA - January 29, 2015 A team at The Scripps Research Institute (TSRI) has won a $1,784,000 grant from the California Institute for Regenerative Medicine (CIRM). The funding will support the development of a new method for detecting DNA damage in stem cells to ensure that only the highest quality cells are used in transplantation or therapy.

Sometimes even the most promising therapy can be derailed by a tiny problem, says Jonathan Thomas, J.D., Ph.D., chair of the CIRM Board, which voted today to fund this and other proposals in the agencys Tools and Technologies initiative. These awards are designed to help find ways to overcome those problems, to bridge the gaps in our knowledge and ensure that the best research is able to keep progressing and move out of the lab and into clinical trials in patients.

Professor Jeanne Loring, Ph.D., is principal investigator for the new TSRI project.

The technology we are developing is similar to that now used for diagnosing cancers, said Loring. In this case, the testwhich is fast and simple to usewill enable researchers to detect abnormal cells in stem cell populations.

Quality control is an important step to ensure the safety and efficacy of potential therapies using stem cellswhich possess the ability to develop into many other distinct cell types, such as nerve, heart, or lung cells, and hold promise for repairing damaged tissue from a range of diseases and injuries.

One line of work funded by the new grant will focus specifically on quality control of potential stem cell therapies for Parkinsons disease.

Another line of work, which includes members of Germanys Federal Ministry of Education and Research, will develop methods for ensuring the reliability of drug screening using stem cells.

For more information, see CIRMs press release (https://www.cirm.ca.gov/about-cirm/newsroom/press-releases/01292015/stem-cell-agency-board-approves-almost-30-million).

Visit link:
San Diego Team Wins $1.7 Million Grant from Stem Cell Agency to Develop Quality Control Methods

Posted in California Stem Cells | Comments Off on San Diego Team Wins $1.7 Million Grant from Stem Cell Agency to Develop Quality Control Methods

Talking Clinical Trials and Stem Cells With One Of Mexico's – Video

Posted: January 29, 2015 at 11:52 am


Talking Clinical Trials and Stem Cells With One Of Mexico #39;s
Talking Clinical Trials and Stem Cells With One Of Mexico #39;s Best Physicians http://www.theclinicaltrials.guru.

By: Dan Sfera

Read the original here:
Talking Clinical Trials and Stem Cells With One Of Mexico's - Video

Posted in Stem Cells | Comments Off on Talking Clinical Trials and Stem Cells With One Of Mexico's – Video

Can hair-growing stem cells cure baldness?

Posted: January 29, 2015 at 11:51 am

LA JOLLA, Calif., Jan. 28 (UPI) -- A new technique for growing human hair in a petri dish may hold promise for balding men and women all over the world. Scientists have managed to grow new hair from human pluripotent stem cells -- cells capable of morphing into all sorts of different cells.

In this instance, the stem cells -- taken from human embryos -- are coaxed into mimicking dermal papillae, the type of cells that govern hair follicle formation and growth cycles. Dermal papillae can be grown in the lab from adult cells, as well, but they quickly lose their potency. Dermal papillae developed from stem cells do not.

"We have developed a method using human pluripotent stem cells to create new cells capable of initiating human hair growth," explained Alexey Terskikh, an associate professor in the Development, Aging, and Regeneration Program at the Sanford-Burnham Medical Research Institute in La Jolla, California.

"The method is a marked improvement over current methods that rely on transplanting existing hair follicles from one part of the head to another," Terskikh added. "Our stem cell method provides an unlimited source of cells from the patient for transplantation and isn't limited by the availability of existing hair follicles."

In studies with mice, transplanted stem-turned-dermal papillae cells were able to grow significant amounts of hair.

The authors of the study -- which was published in the journal PLOS ONE -- are now looking for partners to help take the science to market.

The only problem is that the newly generated stem cell hair grows in a haphazard pattern, each hair shooting in out in different directions and at different angles.

"So it might be a little messy," Terskikh told U-T San Diego. "But I figure that people will prefer messy hair over a lack of it."

2015 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.

Go here to see the original:
Can hair-growing stem cells cure baldness?

Posted in Stem Cells | Comments Off on Can hair-growing stem cells cure baldness?

Stem Cells Could Treat Hair Loss

Posted: January 29, 2015 at 11:51 am

Got too much scalp? A new way to treat hair loss that doesnt involve solutions, creams or hocus-pocus could be on the way.

Scientists at the Sanford-Burnham Medical Research Institute have developed a stem cell method that initiates human hair growth.

Stem Cell Treatment Cures Blindness

Stem cells are the baseline, progenitor cells of all cells in our body. Using a genetic technique, Alexey Terskikh, an associate professor at the institute, and his colleagues coaxed stem cells to become dermal papilla cells.

These cells regulate the formation and growth cycle of hair follicles.

When transplanted into lab mice, the dermal papilla cells promoted the growth of hair.

Stem Cells Grow Beating Heart

Our next step is to transplant human dermal papilla cells derived from human pluripotent stem cells back into human subjects, said Terskikh. We are currently seeking partnerships to implement this final step.

Snake-oil salesmen need not apply.

via Sanford-Burnham Medical Research Institute

Excerpt from:
Stem Cells Could Treat Hair Loss

Posted in Stem Cells | Comments Off on Stem Cells Could Treat Hair Loss

Stem cell-grown hair could help those with hair loss

Posted: January 29, 2015 at 11:51 am

For the first time, researchers have been able to use pluripotent stem cells to generate cells that can grow new hair.

Hair growing on hairless mice thanks to induced pluripotent stem cells. Sanford-Burnham Medical Research Institute

It's been theorised for years, but now human stem cells have resulted in hair growth for the very first time.

"We have developed a method using human pluripotent stem cells to create new cells capable of initiating human hair growth. The method is a marked improvement over current methods that rely on transplanting existing hair follicles from one part of the head to another," said Alexey Terskikh, Ph.D., associate professor in the Development, Aging and Regeneration Program at Sanford-Burnham.

"Our stem cell method provides an unlimited source of cells from the patient for transplantation and isn't limited by the availability of existing hair follicles."

The process started with human pluripotent embryonic stem cells -- that is, stem cells that are capable of developing into any other cell -- which were then developed into neural crest cells. These are cells that can develop into a variety of cells on the head, including brain cells, cartilage, bone and muscle cells.

From the neural crest cell point, the team coaxed the cells to grow into dermal papillae cells, the cells that nourish the skin and regulate follicle growth and formation. When transplanted -- in the case of this study, into hairless mice -- these cells flourish.

Another part of the study examined whether the same result could be achieved using dermal papillae cells taken from the scalps of adult humans. Outside the body, living in culture, these cells are not suitable for hair transplants, since they lost their ability to induce follicle formation. The number of hairs their produced was insignificant.

"In adults, dermal papilla cells cannot be readily amplified outside of the body and they quickly lose their hair-inducing properties," said Terskikh. "We developed a protocol to drive human pluripotent stem cells to differentiate into dermal papilla cells and confirmed their ability to induce hair growth when transplanted into mice."

The researchers say that their research represents the first step towards a cell-based treatment for hair loss, which affects 40 million men and 21 million women in the United States.

See the rest here:
Stem cell-grown hair could help those with hair loss

Posted in Stem Cells | Comments Off on Stem cell-grown hair could help those with hair loss

Friedmann wins Japan Prize for gene therapy

Posted: January 29, 2015 at 11:49 am

Dr. Theodore Friedmann is a longtime faculty member at UC San Diego and a pioneer in gene therapy. / photo by Nelvin C. Cepeda * U-T San Diego

Dr. Theodore Friedmann, a pioneer in the booming field of gene therapy, has been named a 2015 winner of the prestigious Japan Prize.

A pediatrician-turned-researcher at UC San Diego, Friedmann is renowned for demonstrating in the lab that it is possible to correct a genetic defect by adding a functional gene to defective cells, a feat he and colleagues accomplished in 1968. Since then, Friedmann has been guiding the young science through controversies, ethical challenges and setbacks.

Friedmann shares the prize in "medical science and medicinal science" with Dr. Alain Fischer of the Necker Hospital in Paris, France. Fischer helped demonstrate gene therapy's clinical ability to treat a genetic immune deficiency that makes patients extremely vulnerable to infections.

Along with the recognition, Friedmann and Fischer will split a $416,600 award, a certificate and gold medal. There's also the prospect of future recognition: several Japan Prize winners have gone on to win the Nobel Prize.

Friedmann is known not only as a scientist who demonstrated gene therapy is possible, but as a thinker who has dampened the waves of excessive exuberance and despondency that often accompanies the passage of research discoveries into therapies. He has also cautioned his fellow scientists to approach gene therapy with great caution.

In 1972, Friedmann co-authored an influential article in the journal Science, "Gene therapy for human genetic disease?" proposing a program of research advancement and safety precautions with an eye to eventual therapy. In February, 2010, he coauthored an article in Science about the potential use of performance-enhancing "gene doping" in sports.

Those who didn't heed Friedmann's warnings ran into trouble. For example, in 1999 gene therapy patient Jesse Gelsinger, 18, died due to an immune reaction. Gelsinger had a mild form of a genetically caused liver disease, controlled with drugs and diet. He was enrolled to test a treatment to be used in babies with a fatal form of the disease. But Gelsinger himself had little to gain.

A mountain of bad publicity threatened to sink the field. The New York Times wrote about "The Biotech Death of Jesse Gelsinger." As a consequence, other new forms of therapy, such as stem cell treatments, have progressed more slowly to avoid a repeat.

The Gelsinger disaster has receded into the background, as safer forms of gene therapy edge closer to becoming an accepted part of medicine. Forms of gene therapy are now being tested in clinical trials to treat such different diseases as cancer, sickle cell anemia and HIV, with impressive results.

Original post:
Friedmann wins Japan Prize for gene therapy

Posted in Gene therapy | Comments Off on Friedmann wins Japan Prize for gene therapy

Global Stem Cells Group and Regenestem Network Announce Launch of New Stem Cell and Regenerative Medicine Clinic in …

Posted: January 29, 2015 at 11:46 am

MIAMI (PRWEB) January 29, 2015

Regenestem Network, the worlds largest membership network of regenerative medicine practitioners, has announced the launch of a new stem cell clinic in Oaxaca, Mexico. The new facility, offering the most advanced cellular medicine protocols and techniques available is in partnership with Ulises Cervera, M.D. a neurologist coming from the Children's Hospital of Morelia, Mexico.

The new Oaxaca facility will offer the most advanced protocols and techniques available in stem cell medicine to patients from across Mexico and around the world.

Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner.

In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries.

Regenestem offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Oaxaca will have an international staff experienced in administering the latest in cellular therapies.

Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

The Global Stem Cells Group and Regenestem are committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Regenestem Network website, email info(at)regenstem(dot)com, or call 305-224-1858.

About Regenestem: Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena.

More:
Global Stem Cells Group and Regenestem Network Announce Launch of New Stem Cell and Regenerative Medicine Clinic in ...

Posted in Cell Medicine | Comments Off on Global Stem Cells Group and Regenestem Network Announce Launch of New Stem Cell and Regenerative Medicine Clinic in …

Asymmetrex Scheduled to Present Unique Perspectives in Stem Cell Biology and Recent Advances in Technologies for Adult …

Posted: January 29, 2015 at 11:46 am

Boston, MA (PRWEB) January 29, 2015

Dr. James Sherley, Director of the new biotech start-up Asymmetrex, LLC (formerly known as The Adult Stem Cell Technology Center, LLC) is looking forward to four upcoming opportunities in 2015 to continue to impress both academic and industry audiences with his companys very frank take on what is needed to accelerate progress in stem cell medicine.

Asymmetrex has set the focus for its efforts on adult stem cells that are found in the organs and tissues of children and adults. Unlike human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), adult stem cells are free of induced mutations, are not tumor-forming, and have the essential ability to continuously regenerate mature human tissue cells like those in children and adults. To date, hESCs and iPSCs have only been able to regenerate immature cells, and even those not continuously.

Previously, the two main challenges hindering wider use of adult stem cells for drug development and medical therapies have been difficulty producing them and difficulty counting them. Asymmetrex has reported, and in many cases secured patents for, new technologies that reduce or eliminate both of these challenges. At the coming conferences, Dr. Sherley will describe the companys most recent technological advances in this regard and discuss the science that led to them.

In particular, he will highlight the companys newest technology developed with partner AlphaSTAR Corporation for estimating adult stem cell number in any human tissue. The two companies are developing the new technology as an assay to detect drug candidates that will fail in expensive pre-clinical animal studies and clinical trials because of intolerable toxicity against tissue stem cells. By screening-out such drugs earlier in the drug development process, Asymmetrex and AlphaSTAR estimate that together they could save the U.S. pharmaceutical industry $4-5 billion each year.

The four scheduled conferences include the 7th Annual Predictive Toxicology Summit, February 16-18, in London; the 5th World Congress on Cell and Stem Cell Research, March 23-25, in Chicago; the 2015 Annual Meeting at Experimental Biology, March 28-April 1, in Boston; and the Inaugural 3D Cellular Models Conference, June 11-12, also in Boston.

The breadth of conference topics reflects the many important roles that adult tissue stem cells play in human biology and cellular medicine. Dr. Sherley offers that, Because of the importance of adult stem cells in normal body function, it is not surprising that Asymmetrexs technologies impact so many different facets of stem cell biology, regenerative medicine, and drug development.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrexs focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

See the original post here:
Asymmetrex Scheduled to Present Unique Perspectives in Stem Cell Biology and Recent Advances in Technologies for Adult ...

Posted in Cell Medicine | Comments Off on Asymmetrex Scheduled to Present Unique Perspectives in Stem Cell Biology and Recent Advances in Technologies for Adult …

Stem Cell Therapy + PRP Helps Shoulder Injury and Whiplash Patient – Denise Lawson – Video

Posted: January 29, 2015 at 11:45 am


Stem Cell Therapy + PRP Helps Shoulder Injury and Whiplash Patient - Denise Lawson
Denise Lawson experienced two motor vehicle accidents in 2001 that left her with neck pain, headaches, and sporadic episodes of weakness on the left side of her body. Over time, Denise developed...

By: StemCell ARTS

Excerpt from:
Stem Cell Therapy + PRP Helps Shoulder Injury and Whiplash Patient - Denise Lawson - Video

Posted in Cell Therapy | Comments Off on Stem Cell Therapy + PRP Helps Shoulder Injury and Whiplash Patient – Denise Lawson – Video

Page 1,871«..1020..1,8701,8711,8721,873..1,8801,890..»